Document 0795
 DOCN  M94B0795
 TI    Liposome encapsulated doxorubicin for the treatment of AIDS-associated
       Kaposi's sarcoma (Meeting abstract).
 DT    9412
 AU    Harrison M; Coker R; Tomlinson D; Stewart S; Dept. of Oncology, St
       Mary's Hosp., London W2 1NY, UK
 SO    Proc Annu Meet Am Assoc Cancer Res; 35:A1139 1994. Unique Identifier :
       AIDSLINE ICDB/94602825
 AB    Severe KS requiring chemotherapy affects 20-30% of patients with AIDS.
       Doxorubicin within a polyethylene glycol containing liposome (Doxil,
       LTI) has been used in a phase 2 study on 34 patients with severe KS. The
       liposome is 90 nm in diameter and is composed of 20% cholesterol, 20%
       polyethylene glycol, and 60% phosphatidyl choline. Polyethylene glycol
       within the lipid membrane decreases uptake by the reticuloendothelial
       system resulting in a half-life of 33-43 hours. A dose of 20 mg/m2 of
       doxorubicin was given 2-3 times weekly on an outpatient basis via
       peripheral venous access. A total number of 138 treatments were given,
       the maximum for any single patient was 20. A response rate of 76% was
       observed with 2 (6%) CR and 24 (70%) PR. Toxicity was mild, 3 patients
       (9%) developed WHO grade I alopecia and 6 patients (18%) WHO grade I
       nausea and vomiting. Antiemetics were not routinely given and not all
       these episodes of nausea were attributed to Doxil. Quality of life
       assessments showed that Doxil to be well tolerated with minimal
       interruption in the patients lifestyle.
 DE    Acquired Immunodeficiency Syndrome/BLOOD/*DRUG THERAPY
       Doxorubicin/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/  PHARMACOKINETICS
       Drug Carriers  Human  Liposomes  Metabolic Clearance Rate/PHYSIOLOGY
       Sarcoma, Kaposi's/BLOOD/*DRUG THERAPY  Skin Neoplasms/BLOOD/*DRUG
       THERAPY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).